Q
Qingdao Nuoan Baite Biotechnology
Bacteriophage-based antibiotic alternatives for agricultural biotherapy
About Qingdao Nuoan Baite Biotechnology
Founded in 2017 by Chairman Pan Qiang, Qingdao Nuoan Baite Biotechnology Co., Ltd. is a Chinese enterprise focused on developing bacteriophage preparations as an alternative to antibiotics for the agricultural sector. Pan Qiang, a professor at Qingdao Agricultural University with a post-doctoral background from the U.S., leveraged his extensive experience in new veterinary drug R&D to establish the company. The firm addresses the growing problem of antimicrobial resistance by providing biotherapy solutions for drug-resistant bacterial infections.
The company's business model centers on the research, development, production, and sale of bacteriophage products. Its target clients are in the livestock, poultry, aquaculture, pet, and horticulture industries. It also explores solutions for human health. A key corporate asset is its large repository of drug-resistant bacteria and bacteriophage strains, which underpins its R&D efforts. The company operates out of China's first GMP-certified factory for bacteriophage production, aiming to support healthy farming practices and improve food safety. In March 2023, the company, also known as PhagePharm, raised $11.7M in a Series B funding round.
Qingdao Nuoan Baite has developed a range of phage solutions targeting pathogens like E. coli, Salmonella, and various aquatic bacteria. The company has received 44 national invention patents and has over 108 national microbial strain preservation certificates. It has also published more than 50 academic papers, highlighting its commitment to scientific validation. These achievements have earned it recognition as a National High-Tech Enterprise and a Shandong Provincial Gazelle Enterprise, among other accolades.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 17.0/100
- Industry
- Gaming
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2023 | $14M | $55M | Qianji Capital · Morningside Venture Partners | ↗ |
| EARLY VC✓Equity / VC | Jan 2021 | $0 | — | Houxin Jiantou Private Equity Fund Management | ↗ |
Growth signals
Latest recorded traffic for Qingdao Nuoan Baite Biotechnology is 770 monthly website visits, up 71.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qingdao Nuoan Baite Biotechnology in its local ecosystem
The Qingdao Nuoan Baite Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Milestone Venture Group- HGHaidu Group
Series A4 investors entered at this stage
- SVSunshine Ventures
- HMHouxin Jiantou Private Equity Fund Management
- QCQianji Capital
Morningside Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qingdao Nuoan Baite Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qingdao Nuoan Baite Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









